Analyzing Presbia PLC (LENS) & Varian Medical Systems (VAR)
Presbia PLC (NASDAQ: LENS) and Varian Medical Systems (NYSE:VAR) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, earnings, risk, institutional ownership, dividends and valuation.
Earnings and Valuation
This table compares Presbia PLC and Varian Medical Systems’ top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||NetIncome||Earnings Per Share||Price/Earnings Ratio|
|Presbia PLC||$10,000.00||6,420.00||-$15.75 million||($1.20)||-3.12|
|Varian Medical Systems||$2.67 billion||3.72||$249.60 million||$2.69||40.24|
Varian Medical Systems has higher revenue and earnings than Presbia PLC. Presbia PLC is trading at a lower price-to-earnings ratio than Varian Medical Systems, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
Presbia PLC has a beta of 0.2, indicating that its share price is 80% less volatile than the S&P 500. Comparatively, Varian Medical Systems has a beta of 0.65, indicating that its share price is 35% less volatile than the S&P 500.
This is a summary of current ratings for Presbia PLC and Varian Medical Systems, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Varian Medical Systems||2||7||1||0||1.90|
Presbia PLC currently has a consensus price target of $11.33, indicating a potential upside of 202.22%. Varian Medical Systems has a consensus price target of $97.83, indicating a potential downside of 9.61%. Given Presbia PLC’s stronger consensus rating and higher possible upside, equities analysts clearly believe Presbia PLC is more favorable than Varian Medical Systems.
This table compares Presbia PLC and Varian Medical Systems’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Varian Medical Systems||8.85%||23.68%||10.74%|
Insider & Institutional Ownership
16.5% of Presbia PLC shares are owned by institutional investors. Comparatively, 99.2% of Varian Medical Systems shares are owned by institutional investors. 74.7% of Presbia PLC shares are owned by company insiders. Comparatively, 0.9% of Varian Medical Systems shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Varian Medical Systems beats Presbia PLC on 8 of the 13 factors compared between the two stocks.
About Presbia PLC
Presbia PLC is an ophthalmic device company. The Company develops and markets an optical lens implant for treating presbyopia, the age-related loss of the ability to focus on near objects. The Company’s segment is the restoration of clear vision caused by presbyopia. The Company provides the refractive lens for patient surgeries and accessories for procedures performed exclusively outside the United States. The Company’s lens, referred to as the microlens, is a miniature lens designed to be surgically implanted in a patient’s eye to improve that patient’s ability to see objects at close distances. The microlens is a disc shaped lens that has a refractive zone in the periphery designed to improve near vision problems associated with presbyopia and a central zone that is designed to improve distance vision. The Company’s solution is a standalone solution for plano presbyopes, or those individuals suffering from presbyopia but do not have any other visual disorders.
About Varian Medical Systems
Varian Medical Systems, Inc. is a manufacturer of medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, proton therapy and brachytherapy medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, proton therapy and brachytherapy. The Company also has Varian Particle Therapy (VPT) and the operations of the Ginzton Technology Center (GTC). Its VPT business develops, designs, manufactures, sells and services products and systems for delivering proton therapy, another form of external beam radiotherapy using proton beams for the treatment of cancer. Its ProBeam system is capable of delivering intensity modulated proton therapy (IMPT) using pencil beam scanning technology. Its ProBeam Compact is a single room proton therapy product.
Receive News & Ratings for Presbia PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Presbia PLC and related companies with MarketBeat.com's FREE daily email newsletter.